- Study Director: Peter Ljubenkov, MD
- Sponsor: Bristol-Myers Squibb
- Status: Recruiting (screening closes March 28, 2025)
- Official Study Title: A Randomized, Double-blind, Placebo-controlled, Global, Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease (TargetTau-1)
- ClinicalTrials.gov Identifier: NCT06268886
- Conditions Studied: Mild cognitive impairment (MCI), Alzheimer's disease (AD)
- Intervention: BMS-986446
- Phase: Phase 2
- Duration of Participation: Up to 2 years including the screening period
Purpose of the Study
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
Eligibility
Inclusion Criteria
Exclusion Criteria
What to Expect
Testing: Neurological and physical examinations, cognitive testing and neuropsychiatric assessments, telephone calls, blood and urine specimen collection, vital signs, and a PET scan
The Frequency of Visits: Visits occur every 4 weeks
Materials Needed Before Evaluation: Prior to participating in the trial, the patient will need a diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild AD dementia consistent with the National Institute on Aging and the Alzheimer's Association (NIA-AA) core clinical criteria.
Costs: No costs will be charged for any of the study procedures. Parking will be reimbursed.
Contact Information
Coordinator: [email protected]
Clinical Trials Nurse: Whitney Walker, MS, CNS, RN – [email protected], 415.353.7532
